Xbrane Biopharma AB · OMXSTO:XBRANE
Xbrane Biopharma AB — Q1 2022 Earnings Presentation
11 slides from Xbrane Biopharma AB's earnings presentation, May 5, 2022
Slide 1: Xbrane Biopharma AB Presentation Interim Report January - March 2022
Xbrane Biopharma AB Presentation Interim Report January - March 2022 “The agreement with Biogen confirms Xbrane as a leading global Biosimilar Developer” Martin Åmark, CEO Solna May 5 th, 2022 SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January – March 2022
Slide 2: Disclaimer
Disclaimer You must read the following before continuing. The following applies to this document and the information provided in Company may alter. modify or otherwise change in any manner the content of this presentation. without obligation to this presentation by Xbrane Biopharma AB (publ) (the “C
Slide 3: Xbrane has a portfolio addressing €32 billion of reference product sales
Xbrane has a portfolio addressing €32 billion of reference product sales Reference Patent Sales Development Commercializatio Candidate Indication Next milestone Product Expiry 2021 Phase n Partner • Age-related macular Q1 2022 : US regulatory degeneration 2020/22 XlucaneTM • Diabetic macular edema,
Slide 4: Focus for 2022
Focus for 2022 Candidate Focus for 2022 • Apply for market approval in US • Obtain market approval in Europe Xlucane TM • Production of launch volume (post patent expiry of originator) • Prepare for launch (STADA and B+L) • Scale up of production process with AGC Biologics Xcimzane TM • Prepare for
Slide 5: Ambition to be the most attractive employer within our field
Ambition to be the most attractive employer within our field Certified as a Great Place to Work® Equality Managment team No of employees +61% YoY 70 64* 60 58 54 54 50 Women Men Women Women 45 40 Experience 50 30 International 45 20 40 35 10 30 25 0 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 22 Foreign Sweden 2
Slide 6: Upcoming Capital Market Events 2022
Upcoming Capital Market Events 2022 Life Science Summit Pareto Xbrane Capital Market Day May 19, 2022 September, 2022 Q4 2022 SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January – March 2022
Slide 7: Interim Report January – March 2022, Financials
Interim Report January – March 2022, Financials SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January – March 2022
Slide 8: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 0 Total Company Expenses decreased with -8 -8,6 -8,8 -6 -7,9 approximately 20% in the first quarter of 2022 -10 Mainly driven by reclassification of XlucaneTM -20 -28,9 meeting the classification criteria of IAS 38 as of -36,5 -35,9 J
Slide 9: Company Expenses (G&A and R&D)
Company Expenses (G&A and R&D) Comparing “like-for-like” year-on-year, the total Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 0 Operating Costs have increased with 38.5% -8 -8,6 -8,8 -6 -7,9 -10 The total R&D costs (incl. Intangible Asset of SEK -20 -28,9 29.9m) amount to SEK 65.8m, 89.3% of the total -35,9 -
Slide 10: Cash and Cash Equivalents Shareholders' Equity
Cash and Cash Equivalents Shareholders’ Equity 450 500 462,4 400 383,4 450 431,7 396,3 350 400 295,2 301,5 350 300 239,2 300 250 249,7 250 200 208,4 200 150 129,3 150 100 100 50 50 0 0 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 At the end of the first quarter 2022, Cash am
Slide 11: Q&A
Q&A SCIENCE FOR HIGH QUALITY BIOSIMILARS Xbrane Biopharma Interim Report January – March 2022